pegdinetanib
Term · Oncology and biomedicine · MLC-T-ONC-015905
A highly specific, synthetic peptide vascular endothelial growth factor receptor-2 (VEGFR-2) antagonist with potential antiangiogenic activity. Derived from human fibronectin with a proprietary protein engineering process, pegdinetanib may block the activation of VEGFR-2 by all known activating ligands, thereby inhibiting the growth of new tumor blood vessels.
| Identifier | MLC-T-ONC-015905 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | VEGFR-2 inhibitor peptide CT-322 |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-015905",
"term": "pegdinetanib",
"field": "Oncology and biomedicine",
"definition": "A highly specific, synthetic peptide vascular endothelial growth factor receptor-2 (VEGFR-2) antagonist with potential antiangiogenic activity. Derived from human fibronectin with a proprietary protein engineering process, pegdinetanib may block the activation of VEGFR-2 by all known activating ligands, thereby inhibiting the growth of new tumor blood vessels.",
"synonyms": [
"VEGFR-2 inhibitor peptide CT-322"
],
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/pegdinetanib/"
}
Record 12,843 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.